



**TO THE SPANISH NATIONAL SECURITIES MARKET COMMISSION  
(COMISIÓN NACIONAL DEL MERCADO DE VALORES)**

Madrid, 12 September 2024

In compliance with the information duties provided for in article 227 of the Law 6/2023, of 17 March, on the Securities Markets and Investment Services, Laboratorios Farmacéuticos ROVI, S.A. (hereinafter, "**ROVI**" or the "**Company**") hereby discloses to the Spanish National Market Commission the following

**OTHER RELEVANT INFORMATION**

Following the communication of other relevant information number 30,108 and dated 1 August 2024, it is hereby informed that the public deed relating to the share capital reduction in the amount of EUR 166,823.70, through the redemption of 2,780,395 treasury shares of the Company, has been registered with the Commercial Registry of Madrid. Such shares have been delisted with effect on 13 September 2024 on the Stock-Exchange Interconnection System (*Sistema de Interconexión Bursátil*) and on the Madrid, Barcelona, Bilbao and Valencia Stock Exchanges.

As a result, the share capital of the Company has been set at an amount of EUR 3,074,145.72, divided into 51,235,762 ordinary shares, with a nominal value of EUR 0.06 each, which grant a total of 51,235,762 voting rights (one per share). By redeeming these shares, the shareholders automatically increase their percentage interest in the capital stock.

The share capital reduction was approved by the Ordinary General Shareholders' Meeting of the Company held on 24 June 2024, under item Ninth of its agenda.

As a result of this operation, article 5 of ROVI's bylaws have been amended and reads now as follows:



***“Article 5.- Share capital and shares***

*The share capital is 3,074,145.72 euros. It is divided into 51,235,762 ordinary shares with a par value of 0.06 euros each, belonging to a single class and series. All the shares are fully subscribed and paid and all grant their holders the same political and economic rights.”*

Mr. Juan López-Belmonte Encina

Chairman of the Board of Directors and Chief Executive Officer (*Consejero Delegado*)  
Laboratorios Farmacéuticos ROVI, S.A.